p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers

Devor,Eric J.; Gonzalez-Bosquet,Jesus; Warrier,Akshaya; Reyes,Henry D.; Ibik,Nonye V.; Schickling,Brandon M.; Newtson,Andreea; Goodheart,Michael J.; Leslie,Kimberly K.

doi:10.3892/ijo.2017.3931

p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers

Authors:
- Eric J. Devor
- Jesus Gonzalez-Bosquet
- Akshaya Warrier
- Henry D. Reyes
- Nonye V. Ibik
- Brandon M. Schickling
- Andreea Newtson
- Michael J. Goodheart
- Kimberly K. Leslie
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, University of Iowa Carver College of Medicine and The University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
Published online on: March 23, 2017 https://doi.org/10.3892/ijo.2017.3931
Pages: 1721-1728

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Placenta-specific protein 1 (PLAC1) expression is co-opted in numerous human cancers. As a consequence of PLAC1 expression, tumor cells exhibit enhanced proliferation and invasiveness. This characteristic is associated with increased aggressiveness and worse patient outcomes. Recently, the presence of the tumor suppressor p53 was shown in vitro to inhibit PLAC1 transcription by compromising the P1, or distal/cancer, promoter. We sought to determine if this phenomenon occurs in primary patient tumors as well. Furthermore, we wanted to know if p53 mutation influenced PLAC1 expression as compared with wild-type. We chose to study serous ovarian tumors as they are well known to have a high rate of p53 mutation. We report herein that the phenomenon of PLAC1 transcription repression does occur in serous ovarian carcinomas but only when TP53 is wild-type. We find that mutant or absent p53 protein de-represses PLAC1 transcription. We further propose that the inability of mutant p53 to repress PLAC1 transcription is due to the fact that the altered TP53 protein is unable to occupy a putative p53 binding site in the PLAC1 P1 promoter thus allowing transcription to occur. Finally, we show that PLAC1 transcript number is significantly negatively correlated with patient survival in our samples. Thus, we suggest that characterizing tumors for TP53 mutation status, p53 protein status and PLAC1 transcription could be used to predict likely prognosis and inform treatment options in patients diagnosed with serous ovarian cancer.

View Figures

View References

1	Cocchia M, Huber R, Pantano S, Chen EY, Ma P, Forabosco A, Ko MS and Schlessinger D: PLAC1 an Xq26 gene with placenta-specific expression. Genomics. 68:305–312. 2000. View Article : Google Scholar : PubMed/NCBI
2	Massabbal E, Parveen S, Weisoly DL, Nelson DM, Smith SD and Fant M: PLAC1 expression increases during trophoblast differentiation: Evidence for regulatory interactions with the fibroblast growth factor-7 (FGF-7) axis. Mol Reprod Dev. 71:299–304. 2005. View Article : Google Scholar : PubMed/NCBI
3	Fant M, Barerra-Saldana H, Dubinsky W, Poindexter B and Bick R: The PLAC1 protein localizes to membranous compartments in the apical region of the syncytiotrophoblast. Mol Reprod Dev. 74:922–929. 2007. View Article : Google Scholar
4	Devor EJ: Placenta-specific protein 1 is conserved throughout the Placentalia under purifying selection. Sci World J. 2014:5373562014. View Article : Google Scholar
5	Jackman SM, Kong X and Fant ME: Plac1 (placenta-specific 1) is essential for normal placental and embryonic development. Mol Reprod Dev. 79:564–572. 2012. View Article : Google Scholar : PubMed/NCBI
6	Chang W-L, Yang Q, Zhang H, Lin H-Y, Zhou Z, Lu X, Zhu C, Xue LQ and Wang H: Role of placenta-specific protein 1 in trophoblast invasion and migration. Reproduction. 148:343–352. 2014. View Article : Google Scholar : PubMed/NCBI
7	Chen J, Pang X-W, Liu F-F, Dong X-Y, Wang H-C, Wang S, Zhang Y and Chen WF: PLAC1/CP1 gene expression and autologous humoral immunity in gastric cancer patients. Beijing Da Xue Xue Bao. 38:124–127. 2006.In Chinese. PubMed/NCBI
8	Koslowski M, Sahin U, Mitnacht-Kraus R, Seitz G, Huber C and Türeci O: A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. Cancer Res. 67:9528–9534. 2007. View Article : Google Scholar : PubMed/NCBI
9	Silva WA Jr, Gnjatic S, Ritter E, Chua R, Cohen T, Hsu M, Jungbluth AA, Altorki NK, Chen YT, Old LJ, et al: PLAC1 a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. Cancer Immun. 7:182007.
10	Dong X-Y, Peng J-R, Ye Y-J, Chen H-S, Zhang L-J, Pang XW, Li Y, Zhang Y, Wang S, Fant ME, et al: Plac1 is a tumor-specific antigen capable of eliciting spontaneous antibody responses in human cancer patients. Int J Cancer. 122:2038–2043. 2008. View Article : Google Scholar : PubMed/NCBI
11	Liu F-F, Dong X-Y, Pang X-W, Xing Q, Wang H-C, Zhang HG, Li Y, Yin YH, Fant M, Ye YJ, et al: The specific immune response to tumor antigen CP1 and its correlation with improved survival in colon cancer patients. Gastroenterology. 134:998–1006. 2008. View Article : Google Scholar : PubMed/NCBI
12	Tchabo NE, Mhawech-Fauceglia P, Caballero OL, Villella J, Beck AF, Miliotto AJ, Liao J, Andrews C, Lele S, Old LJ, et al: Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer Immun. 9:62009.PubMed/NCBI
13	Devor EJ and Leslie KK: The oncoplacental gene placenta-specific protein 1 is highly expressed in endometrial tumors and cell lines. Obstet Gynecol Int. 2013:8078492013. View Article : Google Scholar : PubMed/NCBI
14	Devor EJ, Reyes HD, Santillan DA, Santillan MK, Onukwugha C, Goodheart MJ and Leslie KK: Placenta-specific protein 1: A potential key to many oncofetal-placental OB/GYN research questions. Obstet Gynecol Int. 2014:6789842014. View Article : Google Scholar : PubMed/NCBI
15	Ghods R, Ghahremani MH, Madjd Z, Asgari M, Abolhasani M, Tavasoli S, Mahmoudi AR, Darzi M, Pasalar P, Jeddi-Tehrani M, et al: High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma. Cancer Immunol Immunother. 63:1319–1327. 2014. View Article : Google Scholar : PubMed/NCBI
16	Liu F-F, Shen D, Kang X, Zhang C and Song Q: New tumor antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma. J Clin Pathol. 68:913–916. 2015. View Article : Google Scholar : PubMed/NCBI
17	Chen Y, Moradin A, Schlessinger D and Nagaraja R: RXRα and LXR activate two promoters in placenta- and tumor-specific expression of PLAC1. Placenta. 32:877–884. 2011. View Article : Google Scholar : PubMed/NCBI
18	Chen Y, Schlessinger D and Nagaraja R: T antigen transformation reveals Tp53/RB-dependent route to PLAC1 transcription activation in primary fibroblasts. Oncogenesis. 2:e672013. View Article : Google Scholar : PubMed/NCBI
19	Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al: Mutational landscape and significance across 12 major cancer types. Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
20	Santillan MK, Leslie KK, Hamilton WS, Boese BJ, Ahuja M, Hunter SK and Santillan DA: 'Collection of a lifetime: A practical approach to developing a longitudinal collection of women's healthcare biological samples'. Eur J Obstet Gynecol Reprod Biol. 179:94–99. 2014. View Article : Google Scholar : PubMed/NCBI
21	Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem. 150:76–85. 1985. View Article : Google Scholar : PubMed/NCBI
22	Joerger AC and Fersht AR: Structure-function-rescue: The diverse nature of common p53 cancer mutants. Oncogene. 26:2226–2242. 2007. View Article : Google Scholar : PubMed/NCBI
23	Wang B, Xiao Z and Ren EC: Redefining the p53 response element. Proc Natl Acad Sci USA. 106:14373–14378. 2009. View Article : Google Scholar : PubMed/NCBI
24	Devor EJ: Placenta-specific protein 1 (PLAC1) is a unique onco-fetal-placental protein and an underappreciated therapeutic target in cancer. Integr Cancer Sci Therap. 3:479–483. 2016. View Article : Google Scholar
25	Brachova P, Thiel KW and Leslie KK: The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci. 14:19257–19275. 2013. View Article : Google Scholar : PubMed/NCBI
26	Blagosklonny MV: p53 from complexity to simplicity: Mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J. 14:1901–1907. 2000. View Article : Google Scholar : PubMed/NCBI
27	Lane DP: Cancer p53 guardian of the genome. Nature. 358:15–16. 1992. View Article : Google Scholar : PubMed/NCBI
28	Freed-Pastor WA and Prives C: Mutant p53: One name, many proteins. Genes Dev. 26:1268–1286. 2012. View Article : Google Scholar : PubMed/NCBI
29	Allen MA, Andrysik Z, Dengler VL, Mellert HS, Guarnieri A, Freeman JA, Sullivan KD, Galbraith MD, Luo X, Kraus WL, et al: Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. eLife. 3:e022002014. View Article : Google Scholar : PubMed/NCBI
30	Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, Dai D, Thiel KW, Devor EJ and Leslie KK: TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol. 46:607–618. 2015.
31	Rinn JL and Huarte M: To repress or not to repress: This is the guardian's question. Trends Cell Biol. 21:344–353. 2011. View Article : Google Scholar : PubMed/NCBI